XML 45 R35.htm IDEA: XBRL DOCUMENT
v3.23.1

Acquisitions, Research Collaborations and License Agreements (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Apr. 30, 2023 | Feb. 28, 2023 | Jan. 31, 2023 | Sep. 30, 2023 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022
Business Acquisition [Line Items] |  |  |  |  |  |  |
Research and development |  |  |  |  | $ 4,276 | $ 2,576 |
Prometheus Biosciences, Inc. | Subsequent Event |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Asset acquisition, share price (in dollars per share) | $ 200 |  |  |  |  |  |
Asset acquisition, price of acquisition, expected | $ 10,800 |  |  |  |  |  |
Research and development |  |  |  | $ 10,300 |  |  |
Imago Bio Sciences, Inc. |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Research and development |  |  | $ 1,200 |  |  |  |
Asset acquisition costs |  |  | 60 |  |  |  |
Net assets acquired |  |  | 219 |  |  |  |
Consideration transferred, asset acquisition |  |  | 1,350 |  |  |  |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Research and development |  | $ 175 |  |  |  |  |
Eligible future contingent development-related payments (up to) |  | 1,000 |  |  |  |  |
Regulatory milestones payments |  | 2,800 |  |  |  |  |
Sales milestone payments |  | $ 5,500 |  |  |  |  |
Preferred stock investment in counterparty |  |  | $ 100 |  |  |  |
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Alliance revenue - Lenvima |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Capitalized milestone payment |  |  |  |  |  | $ 25 | $ 50

X
- Definition Asset Acquisition, Assets Acquired And Liabilities Assumed, Net + References No definition available. + Details
Name: | mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in an asset acquisition. + References No definition available. + Details
Name: | mrk_AssetAcquisitionSharePrice
Namespace Prefix: | mrk_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Preferred Stock Investment In Counterparty + References No definition available. + Details
Name: | mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments + References No definition available. + Details
Name: | mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments + References No definition available. + Details
Name: | mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments + References No definition available. + Details
Name: | mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone Payments Made to Collaborative Partner + References No definition available. + Details
Name: | mrk_MilestonePaymentsMadetoCollaborativePartner
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 55 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction cost incurred as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 55 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 15 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492 + Details
Name: | us-gaap_AssetAcquisitionPriceOfAcquisitionExpected
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=mrk_PrometheusBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=mrk_ImagoBioSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_EisaiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |